Inclusion Criteria:

- Female or male aged 25 or over

- Histological diagnosis of locally advanced or metastatic gastro adenocarcinoma
(including adenocarcinoma of the lower third of the oesophagus or the gastro
oesophageal junction )

- Radiographically confirmed progression after 1 prior chemotherapy or
chemoradiotherapy for gastric cancer. Suitable for and expected to benefit from
paclitaxel monotherapy.

- At least one lesion, not previously irradiated, that has baseline at least 10mm in
the longest diameter for non nodal lesions and is assessed by Computerised
Tomography (CT) or Magnetic Resonance Imaging (MRI)

- Provision of either an archival tumour sample or a fresh tumour sample for
confirmation of FGFR2 polysomy/gene amplification

Exclusion Criteria:

- Prior exposure to AZD4547 or history of hypersensitivity other drugs similar in
structure or class to AZD4547. Hypersensitivity to paclitaxel or formulated in
cremophor EL (polyoxyethylated castor oil)

- Prior taxane treatment for gastric cancer with the exception of adjuvant/neo-adjuvant
therapy given > 6 months; Major surgery, radiotherapy with wide field of radiation or
any cancer treatment within 4 weeks before the first dose of the study treatment

- With the exception of alopecia, any unresolved toxicities from prior therapy with a
Common Terminology Criteria for AE (CTCAE) grade >1 at the time of starting study
treatment.

- Blood and Echocardiogram (ECG) readings that are deemed to be abnormal by falling
outside of the reference ranges in the protocol inclusion/exclusion section.

- Taking other regular medication that are predicted to interact with AZD4547 due to
their route of metabolism.